Confirm a stable target identifier before relying on this context across project surfaces.
CHEMBL614818 Target Snapshot
HEK293 · CELL-LINE · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Confirm a stable target identifier before relying on this context across project surfaces.
HEK293
Review this target as HEK293.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats HEK293 as ChEMBL target CHEMBL614818. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether HEK293 still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need the strongest disease program and evidence level in one place.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | HEK293 |
| Target Type | CELL-LINE |
| Organism | Homo sapiens |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
How to read this target
Review this target as HEK293.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4794117 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL4800456 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL3822907 | 9.89 | IC50 | 0.1278 | Preclinical |
| CHEMBL15177 | 9.8 | IC50 | 0.16 | Preclinical |
| CHEMBL4094083 | 9.77 | IC50 | 0.17 | Preclinical |
| CHEMBL4075161 | 9.64 | IC50 | 0.23 | Preclinical |
| CHEMBL4066549 | 9.62 | IC50 | 0.242 | Preclinical |
| CHEMBL139702 | 9.55 | IC50 | 0.28 | Preclinical |
| CHEMBL3823024 | 9.51 | IC50 | 0.3065 | Preclinical |
| CHEMBL469912 | 9.46 | IC50 | 0.35 | Clinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
ADME — 1,251 assays, 1,893 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1,251 | 1,893 | 5.2 |
Functional — 868 assays, 1,490 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 864 | 1,490 | 5.4 |
| organism-based format | 4 | 0 | — |
Toxicity — 454 assays, 381 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 454 | 381 | 5.1 |
Binding — 15 assays, 35 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 15 | 35 | 5.8 |
Unassigned — 8 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 8 | 0 | — |